Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Tissue-specific induction of autophagy as an innovative therapeutic strategy in cardiovascular and metabolic disease.

Descrizione del progetto

Autofagia mirata per le malattie metaboliche nel mondo occidentale

Le diete occidentali sono molto caloriche, essendo caratterizzate da un elevato tenore di grassi e zuccheri. Il risultato è un’epidemia di malattie quali l’arterosclerosi e la steatosi epatica non alcolica. Data l’inadeguatezza della conformità del paziente ai cambiamenti nello stile di vita necessari ad affrontare questi disturbi, risulterebbe vantaggioso il trattamento farmacologico. Il progetto CARDIOPHAGY, finanziato dall’UE, sta sviluppando molecole in grado di colpire in modo specifico le cellule disfunzionali bersaglio presenti nel cuore e nel fegato. Le molecole inducono l’autofagia, un processo che rivitalizza le cellule rimuovendo i prodotti tossici di scarto. Tutte le molecole sviluppate saranno testate a fondo per determinarne il potenziale di induzione dell’autofagia e la capacità di targeting, così da consentire la progettazione di farmaci rilevanti.

Obiettivo

Western-style diets are hypercaloric and characterized by high fat and high sugar content. They are responsible for an epidemic of cardiovascular disease, including atherosclerosis (AS), and metabolic disorders, including Non-Alcoholic Fatty Liver Disease (NAFLD). The European population is becoming increasingly exposed to these disorders, for which the only available therapeutic option is lifestyle modification. This typically involves dietary changes and physical activity, but patient compliance with these measures tends to be suboptimal. Pharmacological treatment options could therefore have significant potential to improve patient perspectives.

With this respect, pharmacological induction of autophagy is intensively studied. Autophagy is the main detoxification and recycling mechanism of cells, and it has been shown to become dysfunctional in AS and NAFLD. Small molecules that can stimulate the process have been demonstrated to treat the diseases in animal models. However, all known autophagy-inducing molecules lack specificity, and this is suspected to cause systemic toxicity during chronic application in humans.

In this proposal, we deliver molecules that avoid systemic exposure by targeting them specifically to disease-relevant tissues. First, potent autophagy inducers will be chemically linked to selected homing peptides that we hypothesize to deliver the molecules to dysfunctional vascular endothelial cells in atherosclerosis. Similarly, we hypothesize that triantennary N-acetyl galactosamine (GN3) can guide autophagy inducers to liver cells in the context of NAFLD. All molecules that are prepared in this project will be first studied in cells: both autophagy induction potential and tissue targeting will be evaluated thoroughly. For the best molecule prepared (either endothelial- or liver-targeted), in vivo proof-of-concept will be delivered. In this way, the proposal's potential to deliver new, relevant drugs will be maximally valorized.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2021-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITEIT ANTWERPEN
Contributo netto dell'UE
€ 191 760,00
Indirizzo
PRINSSTRAAT 13
2000 Antwerpen
Belgio
Regione
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato